内镜超声的新兴诊断适应症
本文综述了内镜超声(EUS)在胃肠道及肝胆胰疾病诊断中的新进展,涵盖慢性胰腺炎、胰腺癌液体活检、肝病评估、辅助成像、组织获取、人工智能、胰腺囊肿诊断及个体化治疗模型等领域,推动EUS从「观察与活检」向「检测、预测与个体化」转变。
要点
- EUS在慢性胰腺炎横断面成像不明确时仍居核心地位,促胰液素刺激胰腺功能检测可补充形态学。
- EUS引导的门静脉压力梯度测量和肝活检可同次完成,准确且安全性良好。
- EUS获取组织可用于类器官、患者来源异种移植和器官型切片培养以测试个体化治疗。
核心结论
- EUS已从诊断成像工具演变为集高精度通路、采样和治疗于一体的多功能平台,正迈向检测、预测和个体化。
研究设计与样本
- 本文为综述,总结重塑诊断实践和治疗诊断学的近期进展。
主要发现
- 在慢性胰腺炎中,横断面成像不明确时EUS仍居核心,促胰液素刺激的内镜下胰腺功能检测可补充形态学,但结果不一致限制单独确定性。
- 对于胰腺癌,促胰液素刺激的十二指肠胰液收集可实现「液体活检」分析,包括甲基化DNA标志物和细胞外囊泡microRNA,可补充碳水化合物抗原19-9并可能增强早期检测和囊肿监测。
- 在endohepatology中,EUS引导的门静脉压力梯度测量和肝活检提供准确的同次评估且安全性良好。
- 辅助成像——对比增强EUS和弹性成像——改善病变表征和靶向。
- 组织获取已转向端切细针活检针,通过扇形/扭矩技术、湿抽吸和宏观/可视化现场评估优化,减少穿刺次数同时保持分子充分性。
关键数值与推荐
- 在慢性胰腺炎中,横断面成像不明确时EUS仍居核心;促胰液素刺激的内镜下胰腺功能检测可补充形态学,但结果不一致限制单独确定性。
- 对于胰腺癌,促胰液素刺激的十二指肠胰液收集可实现「液体活检」分析,包括甲基化DNA标志物和细胞外囊泡microRNA,可补充碳水化合物抗原19-9。
- EUS引导的门静脉压力梯度测量和肝活检提供准确、同次评估且安全性良好。
- 对比增强EUS和弹性成像改善病变表征和靶向。
- 端切细针活检针通过扇形/扭矩技术、湿抽吸和宏观/可视化现场评估优化,减少穿刺次数同时保持分子充分性。
临床怎么用
- 在慢性胰腺炎横断面成像不明确时,可考虑EUS联合促胰液素刺激胰腺功能检测。
- 胰腺癌早期检测和囊肿监测中,可利用EUS收集胰液进行液体活检分析。
- 肝病评估中,EUS引导门静脉压力梯度测量和肝活检可同次完成。
- 组织获取优先选择端切细针活检针并采用优化技术以减少穿刺次数。
- EUS获取组织可用于个体化治疗测试模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endoscopic ultrasound (EUS) has evolved from a diagnostic imaging tool into a versatile platform that enables high-precision access, sampling, and therapy across gastrointestinal and hepatobiliary diseases. This review summarizes recent advances that are reshaping diagnostic practice and theragnostics. In chronic pancreatitis, EUS remains central when cross-sectional imaging is equivocal; secretin-stimulated endoscopic pancreatic function testing can complement morphology, although discordant results limit standalone certainty. For pancreatic cancer, secretin-stimulated duodenal pancreatic-juice collection enables "liquid biopsy" analyses-including methylated DNA markers and extracellular-vesicle microRNAs-that augment carbohydrate antigen 19-9 and may enhance early detection and cyst surveillance. In endohepatology, EUS-guided portal pressure gradient measurement and liver biopsy offer accurate, same-session assessment with strong safety profiles. Adjunctive imaging-contrast-enhanced EUS and elastography-improves lesion characterization and targeting. Tissue acquisition has shifted toward end-cutting fine-needle biopsy needles, optimized by fanning/torque techniques, wet-suction, and macroscopic/visual on-site evaluation, reducing passes while preserving molecular adequacy. Artificial intelligence is emerging across workflows-from differentiating pancreatic lesions and staging to automating standardized photodocumentation and reporting-and is being explored for needle-based confocal laser endomicroscopy image interpretation. For pancreatic cysts, glucose, selected genomics (eg, KRAS/GNAS and targeted panels), and through-the-needle biopsy refine diagnosis. Finally, EUS-obtained tissue now seeds organoids, patient-derived xenografts, and organotypic slice cultures to test individualized therapies. Collectively, these innovations move EUS beyond "see and biopsy" toward detect, predict, and personalize.
引用
- Wallace MB, Majumder S, Storz P, et al. Emerging Diagnostic Indications for Endoscopic Ultrasound. Gastroenterology. 2026. PMID: 41498716. doi:10.1053/j.gastro.2025.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。